EMERGING PHARMACOLOGICAL TARGETS IN DIABETIC KIDNEY DISEASE: FROM MOLECULAR MECHANISMS TO PRECISION THERAPEUTICS
Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and an important cause of chronic kidney disease and kidney failure. Although renin–angiotensin system blockade, sodium–glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and non-steroidal mineralocorticoid receptor antagonists have substantially changed the therapeutic landscape, residual risk of kidney disease progression remains. Increasing understanding of glomerular hyperfiltration, podocyte injury, oxidative stress, mitochondrial dysfunction, inflammation and fibrosis has identified new pharmacological opportunities. This review summarizes established pharmacological approaches and emerging molecular targets in DKD, with emphasis on mechanisms, clinical evidence, combination strategies and future precision therapeutics. Clinical evidence from DAPA-CKD, EMPA-KIDNEY, FLOW and FIDELITY demonstrates clinically meaningful renal protection with SGLT2 inhibition, semaglutide and finerenone. Emerging approaches include endothelin-A receptor blockade, aldosterone-synthesis inhibition, anti-inflammatory and anti-fibrotic strategies. Recent combination evidence also suggests that complementary mechanisms may provide greater reduction in albuminuria than monotherapy. DKD pharmacotherapy is therefore transitioning from a predominantly glucose-centered approach toward multi-pathway and potentially precision-based renal protection. Keywords: Diabetic kidney disease; Pharmacology; SGLT2 inhibitors; GLP-1 receptor agonists; Finerenone; Endothelin; NLRP3 inflammasome; Precision medicine.
Authors
- Ch.Gopala Krishna
- N. Mounika
- B. Srinivasa Mani Shankar Reddy
- N. Sri Varshitha
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-20
- DOI
- https://doi.org/10.5281/zenodo.24387299
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00